PHAR vs. VCEL, CNTA, DNLI, KYMR, MIRM, GMTX, BLTE, ARWR, CGON, and HRMY
Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Vericel (VCEL), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), Kymera Therapeutics (KYMR), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Belite Bio (BLTE), Arrowhead Pharmaceuticals (ARWR), CG Oncology (CGON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.
Pharming Group vs.
Vericel (NASDAQ:VCEL) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.
0.0% of Pharming Group shares are owned by institutional investors. 5.2% of Vericel shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Vericel has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500.
Vericel has higher earnings, but lower revenue than Pharming Group. Pharming Group is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.
Vericel has a net margin of 1.56% compared to Pharming Group's net margin of -6.09%. Vericel's return on equity of 1.48% beat Pharming Group's return on equity.
Vericel received 331 more outperform votes than Pharming Group when rated by MarketBeat users. However, 67.65% of users gave Pharming Group an outperform vote while only 61.78% of users gave Vericel an outperform vote.
In the previous week, Vericel had 1 more articles in the media than Pharming Group. MarketBeat recorded 9 mentions for Vericel and 8 mentions for Pharming Group. Vericel's average media sentiment score of 1.71 beat Pharming Group's score of 0.50 indicating that Vericel is being referred to more favorably in the media.
Vericel currently has a consensus price target of $62.29, suggesting a potential upside of 29.87%. Pharming Group has a consensus price target of $30.00, suggesting a potential upside of 244.23%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Vericel.
Summary
Vericel beats Pharming Group on 13 of the 17 factors compared between the two stocks.
Get Pharming Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharming Group Competitors List
Related Companies and Tools
This page (NASDAQ:PHAR) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy PHAR Stock Free PHAR Stock Alerts